From yesterday PR..

" Primary endpoint--- overall response rate..
Strong response signal seen in a sub study may allow for expansion to generate data that could potentially support market approval "

Someone asked question yesterday , how much longer patient must live to satisfy secondary endpoint in cancer study..--

FDA don't need to wait to see how many more months or years patients will be alive ,

If they see that on MRI and scans , tumors are shrinking , no new metastasis , this should be enough for them.

This is a sign that patients life is prolong , and it is accepted sign by FDA.

With Leronlimab , so far we can see shrinking tumors , some gone and no new metastasis withing few weeks after starting therapy ,

If this will mostly continue in our basket trial , since we dealing with the most deadly cancers ,
this should not be a very long study..


IMO as always.